Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis

Journal of the Neurological Sciences

Volumn 259, Issue 1-2, 2007, Pages 27-37

  Neuhaus, Oliver ^a   Kieseier, Bernd C ^a   Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Glatiramer acetate; Immunomodulation; Immunosuppression; Immunotherapy; Interferon beta; Mitoxantrone; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; CYTOKINE; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NEUTRALIZING ANTIBODY;

ARTICLE; CELL DEATH; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; HELPER CELL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; SUPPRESSOR CELL;

ANALGESICS; ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MITOXANTRONE; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 34447096559     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.05.071     Document Type: Article

References (106)

1. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Medical progress: multiple sclerosis. N Engl J Med 343 (2000) 938-952
2. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis. New aspects and practical application. J Neurol 251 (2004) 1329-1339
3. Paty D.W. Interferon beta-1b. In: Hawkins C.P., and Wolinsky J.S. (Eds). Principles of treatments in multiple sclerosis (2000), Butterworth-Heinemann, Oxford, Woburn 24-37
4. Wolinsky J.S. Glatiramer acetate. In: Hawkins C.P., and Wolinsky J.S. (Eds). Principles of treatments in multiple sclerosis (2000), Butterworth-Heinemann, Oxford, Woburn 71-94
5. Goodin D.S. Therapeutic developments in multiple sclerosis. Expert Opin Investig Drugs 9 (2000) 655-670
6. Hartung H.P., Bar-Or A., and Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS?. J Neurol 251 Supplement 5 (2004) V/12-V/29
7. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
8. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R., Richert J.R., Salazar AM., et al. Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 (1996) 285-294
9. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
10. Rovaris M., Confavreux C., Furlan R., Kappos L., Comi G., and Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5 (2006) 343-354
11. European Study Group on Interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352 (1998) 1491-1497
12. Kappos L., Weinshenker B., Pozzilli C., Thompson A.J., Dahlke F., Beckmann K., et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63 (2004) 1779-1787
13. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
14. Hartung H.P., Gonsette R., König N., Kwiecinski H., Guseo A., Morrissey S.P., et al. A placebo-controlled, double-blind, randomised, multicentre trial of mitoxantrone in progressive multiple sclerosis. Lancet 360 (2002) 2018-2025
15. Deisenhammer F., Reindl M., Harvey J., Gasse T., Dilitz E., and Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52 (1999) 1239-1243
16. Buchwalder P.A., Buclin T., Trinchard I., Munafo A., and Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 20 (2000) 857-866
17. Durelli L., Verdun E., Barbero P., Bergui M., Versino E., Ghezzi A., et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359 (2002) 1453-1460
18. Coyle P.K., and Hartung H.P. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult Scler 8 (2002) 2-9
19. Panitch H., Goodin D.S., Francis G., Chang P., Coyle P., et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59 (2002) 1496-1506
20. Alam J., McAllister A., Scaramucci J., Jones W., and Rogge M. Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFNb-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration. Clin Drug Invest 14 (1997) 35-43
21. Freedman M.S., Francis G.S., Sanders E.A.C.M., Rice G.P., O'Connor P., et al. Randomized study of once-weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 11 (2005) 41-45
22. Clanet M., Radue E.W., Kappos L., Hartung H.P., Hohlfeld R., Sandberg-Wollheim M., et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59 (2002) 1507-1517
23. Burks J. Interferon-beta1b for multiple sclerosis. Expert Rev Neurotherap 5 (2005) 153-164
24. Ross C., Clemmesen K.M., Svenson M., Soelberg Sorensen P., Koch-Hendriksen N., Skovgaard G.L., et al. Immunogenecity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 48 (2000) 706-712
25. Soelberg Sorensen P., Ross C., Clemmensen K.M., Bendtzen K., Frederiksen J.L., Jensen K., et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362 (2003) 1184-1191
26. Pachner A.R. Anti-IFN-beta antibodies in IFN-beta-treated MS patients. Neurology 9 Supplement 5 (2003)
27. Namaka M., Pollitt-Smith M., Gupta A., Klowak M., Vasconcelos M., Turcotte D., et al. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. Curr Med Res Opin 22 (2006) 223-239
28. Hemmer B., Stüve O., Kieseier B.C., Schellekens H., and Hartung H.P. Immune response to therapy - the role of neutralizing antibodies to beta-interferons in the treatment of multiple sclerosis. Lancet Neurol 4 (2005) 403-412
29. Ziemssen T., Neuhaus O., and Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Safety 24 (2001) 979-990
30. Lobel E., Riven-Kreitman R., Amselem A., and Pinchasi I. Copolymer-1. Drugs Future 21 (1996) 131-134
31. Ehninger G., Schuler U., Proksch B., Zeller K.P., and Blanz J. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18 (1990) 365-380
32. Faulds D., Balfour J.A., Chrisp P., and Langtry H.D. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41 (1991) 400-449
33. Hu O.Y., Chang S., Law C., Jian J., and Chen K. Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. Cancer 69 (1992) 847-853
34. Canal P., Attal M., Chatelut E., Guichard S., Huguet F., Muller C., et al. Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Res 53 (1993) 4850-4854
35. Ballestrero A., Ferrando F., Garuti A., Basta P., Gonella R., Esposito M., et al. High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule. Br J Cancer 76 (1997) 797-804
36. Repetto L., Vannozzi M.O., Balleari E., Venturino A., Granetto C., Bason C., et al. Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoietic progenitor cells. Anticancer Res 19 (1999) 879-884
37. Stewart D.J., Green R.M., Mikhael N.Z., Montpetit V., Thibault M., and Maroun J.A. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 70 (1986) 1255-1261
38. Lenk H., Müller U., and Tanneberger S. Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 7 (1987) 1257-1264
39. Fox E.J. Mechanism of action of mitoxantrone. Neurology 63 Supplement 6 (2004) S15-S18
40. Jain K.K. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Investig Drugs 9 (2000) 1139-1149
41. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3 (2002) 291-301
42. Lassmann H., Brück W., and Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7 (2001) 115-121
43. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2 (2001) 762-764
44. Neuhaus O., Archelos J.J., and Hartung H.P. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 24 (2003) 131-138
45. Barnett M.H., and Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55 (2004) 458-468
46. Trapp B.D., Ransohoff R.M., and Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12 (1999) 295-302
47. Coleman M.P., and Perry V.H. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 25 (2002) 532-537
48. Stüve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40 (1996) 853-863
49. Leppert D., Waubant E., Bürk M.R., Oksenberg J.R., and Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 40 (1996) 846-852
50. Barna B.P., Chou S.M., Jacobs B., Yen-Lieberman B., and Ransohoff R.M. Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol 23 (1989) 45-53
51. Hall G.L., Compston A., and Scolding N. Beta-interferon and multiple sclerosis. Trends Neurosci 20 (1997) 63-67
52. Yong V.W. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology 59 (2002) 802-808
53. Karpusas M., Whitty A., Runkel L., and Hochman P. The structure of human interferon-beta: implications for activity. Cell Mol Life Sci 54 (1998) 1203-1216
54. Hohlfeld R. Therapeutic strategies in multiple sclerosis. I. Immunotherapy. Philos Trans R Soc Lond B Biol Sci 354 (1999) 1697-1710
55. Liu Z., Pelfrey C.M., Cotleur A., Lee J.C., and Rudick R.A. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 112 (2001) 153-162
56. Rep M.H.G., Hintzen R.Q., Polman C.H., and Van Lier R.A.W. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T cells. J Neuroimmunol 67 (1996) 111-118
57. Pette M., Pette D.F., Muraro P.A., Martin R., and McFarland H.F. Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific T-helper type 1 lymphocytes. Neurology 49 (1997) 385-392
58. Joseph J., Knobler R.L., D'Imperio C., and Lublin F.D. Downregulation of interferon-gamma-induced class II expression on human glioma cells by recombinant interferon-beta: effects of dosage treatment schedule. J Neuroimmunol 20 (1988) 39-44
59. Lu H.T., Riley J.L., Babcock G.T., et al. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility comlex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. J Exp Med 182 (1995) 1517-1525
60. Trojano M., Avolio C., Liuzzi G.M., et al. Changes of serum sICAM-1 and MMP-9 induced by rINFbeta-1b treatment in relapsing-remitting MS. Neurology 53 (1999) 1402-1408
61. Calabresi P.A., Pelfrey C.M., Tranquill L.R., Maloni H., and McFarland H.F. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon-beta. Neurology 49 (1997) 1111-1116
62. Rudick R.A., Ransohoff R.M., Peppler R., VanderBrug-Medendorp S., Lehmann P., and Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 40 (1996) 618-627
63. Rep M.H.G., Schrijver H.M., Van Lopik T., Hintzen R.Q., Roos M.T., et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol 96 (1999) 92-100
64. Van Weyenbergh J., Lipinski P., Abadie A., Chabas D., Blank U., et al. Antagonistic action of IFN-beta and IFN-gamma on high affinity Fcgamma receptor expression in healthy controls and multiple sclerosis patients. J Immunol 61 (1998) 1568-1574
65. Sega S., Wraber B., Mesec A., Horvat A., and Ihan A. IFN-beta 1a and IFN-beta 1b have different patterns of influence on cytokines. Clin Neurol Neurosurg 106 (2004) 255-258
66. Fridkis-Hareli M., and Strominger J.L. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 160 (1998) 4386-4397
67. Gran B., Tranquill L.R., Chen M., Bielekova B., Zhou W., Dhib-Jalbut S., et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 55 (2000) 1704-1714
68. Neuhaus O., Farina C., Wekerle H., and Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56 (2001) 702-708
69. Farina C., Weber M.S., Meinl E., Wekerle H., and Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 4 (2005) 567-575
70. Aharoni R., Teitelbaum D., Arnon R., and Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A 96 (1999) 634-639
71. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Then Bergh F., Dose T., et al. Multiple sclerosis: comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A 97 (2000) 7452-7457
72. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., and Hafler D.A. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105 (2000) 967-976
73. Filippi M., Rovaris M., Rocca M.A., et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 57 (2001) 731-733
74. Khan O., Shen Y., Caon C., Bao F., Ching W., Reznar M., et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11 (2005) 646-651
75. Rovaris M., Comi G., and Filippi M. Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?. J Neurol Sci 233 (2005) 139-143
76. Ziemssen T., Kümpfel T., Klinkert W.E., Neuhaus O., and Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 125 (2002) 2381-2391
77. Chen M., Valenzuela R.M., and Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 215 (2003) 37-44
78. Aharoni R., Kayhan B., Eilam R., Sela M., and Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A 100 (2003) 14157-14162
79. Flügel A., Matsumoto K., Neumann H., et al. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol 31 (2001) 11-22
80. Linker R.A., Maurer M., Gaupp S., Martini R., Holtmann B., Giess R., et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8 (2002) 620-624
81. Butzkueven H., Zhang J.G., Soilu-Hanninen M., et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 8 (2002) 613-619
82. Gilgun-Sherki Y., Panet H., Holdengreber V., Mosberg-Galili R., and Offen D. Axonal damage is reduced following glatiramer acetate treatment in C75/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res 47 (2003) 201-207
83. Angelov D.N., Waibel S., Guntinas-Lichius O., Lenzen M., Neiss W.F., et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 100 (2003) 4790-4795
84. Smith I.E. Mitoxantrone (Novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10 (1983) 103-115
85. Fesen M.R., Kohn K.W., Leteurtre F., and Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A 90 (1993) 2399-2403
86. Huff A.C., and Kreuzer K.N. Evidence for a common mechanism of action of antitumor and antibacterial agents that inhibit type II DNA topoisomerases. J Biol Chem 265 (1990) 20496-20505
87. Stüve O., Cree B.C., von Budingen H.C., Youssef S., Bowen J.D., Genain C.P., et al. Approved and future pharmacotherapy for multiple sclerosis. Neurologist 8 (2002) 290-301
88. Neuhaus O., Kieseier B.C., and Hartung H.P. Mechanisms of mitoxantrone in multiple sclerosis - what is known?. J Neurol Sci 223 (2004) 25-27
89. Fidler J.M., de Joy S.Q., and Gibbons J.J. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 137 (1986) 727-732
90. Fidler J.M., de Joy S.Q., Smith F.R., and Gibbons J.J. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone treated mice. J Immunol 136 (1986) 2747-2754
91. Mauch E., Kornhuber H.H., Krapf H., Fetzer U., and Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 242 (1992) 96-102
92. Gbadamosi J., Buhmann C., Tessmer W., Moench A., Haag F., and Heesen C. Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol 49 (2003) 137-141
93. Bellosillo B., Colomer D., Pons G., and Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 100 (1998) 142-146
94. Neuhaus O., Wiendl H., Kieseier B.C., Archelos J.J., Hemmer B., Stüve O., et al. Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 168 (2005) 128-137
95. Chan A., Weilbach F.X., Toyka K.V., and Gold R. Mitoxantrone induces cell death in peripheral blood leukocytes of multiple sclerosis patients. Clin Exp Immunol 139 (2005) 152-158
96. Gonsette R.E. Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler 1 (1996) 329-332
97. Khoury S.J., Bharanidharan P., Bourcier K., Cook S.L., Stazzone L., and Weiner H.L. Immunologic effects of mitoxantrone therapy in patients with multiple sclerosis. Neurology 58 Supplement 3 (2002) A245-A246
98. Ross T.M., Martinez P.M., Renner J.C., Thorne R.G., Hanson L.R., and Frey W.Hn. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 151 (2004) 66-77
99. Gonsette R.E. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. J Neurol Sci 223 (2004) 81-86
100. Neuhaus O., Stüve O., Archelos J.J., and Hartung H.P. Putative mechanisms of action of statins in multiple sclerosis - comparison to interferon-beta and glatiramer acetate. J Neurol Sci 233 (2005) 173-177
101. Dalal M., Kim S., and Voskuhl R.R. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol 159 (1997) 3-6
102. Soldan S.S., Retuerto A.I., Sicotte N.L., and Voskuhl R.R. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 171 (2003) 6267-6274
103. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
104. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 (2006) 911-923
105. Lublin F.D., and Reingold S.C. Combination therapy for treatment of multiple sclerosis. Ann Neurol 44 (1998) 7-9
106. Wiendl H., and Kieseier B.C. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opin Investig Drugs 12 (2003) 689-712